Shopping Cart
- Remove All
- Your shopping cart is currently empty
GSK-A1 is a specific inhibitor of PI4KA, also inhibited calcium-driven PRL secretion without affecting calcium signaling and Prl expression. GSK-A1 has anti-hepatitis C virus (HCV) potential.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $72 | In Stock | |
5 mg | $168 | Backorder | |
50 mg | Inquiry | Backorder |
Description | GSK-A1 is a specific inhibitor of PI4KA, also inhibited calcium-driven PRL secretion without affecting calcium signaling and Prl expression. GSK-A1 has anti-hepatitis C virus (HCV) potential. |
Targets&IC50 | PI4KB:7.2-7.7 (pIC50), PI4K2B:<5 (pIC50), PI4K2A:<5 (pIC50), PI4KA:8.5-9.8 (pIC50) |
In vitro | GSK-A1 is a selective?type III phosphatidylinositol 4-kinase PI4KA (PI4KIIIα)?inhibitor with a?pIC50?of 8.5-9.8[3]. GSK-A1 potently decreases the levels of PtdIns(4)P with a negligible effect on PtdIns(4,5)P2[3]. |
Molecular Weight | 574.63 |
Formula | C29H27FN6O4S |
Cas No. | 1416334-69-4 |
Smiles | COc1ncc(cc1S(=O)(=O)Nc1ccccc1F)-c1ccc2nc(N)n(-c3ccc(cc3)N3CCOCC3)c2c1 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.